🇺🇸 FDA
Patent

US 11236141

Targeted mutant interferon-beta and uses thereof

granted A61KA61K38/00A61K47/65

Quick answer

US patent 11236141 (Targeted mutant interferon-beta and uses thereof) held by Orionis Biosciences, Inc expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Orionis Biosciences, Inc
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/00, A61K47/65, A61P, A61P35/00